Neuroscience discipline
Aspen Neuroscience Secures $115 Million Series C to Advance Parkinson’s Cell Therapy; IPO Considered for 2026
Aspen Neuroscience; Series C financing; Parkinson’s disease; cell therapy; ANPD001; autologous iPSC; clinical trials; manufacturing scale-up; IPO plans; regenerative medicine
Neuphoria Scraps Social Anxiety Drug After Trial Failure; Minerva Doubles Down on Schizophrenia Therapy
Neuphoria Therapeutics; BNC210; social anxiety disorder; AFFIRM-1 phase 3 trial; clinical trial failure; program discontinuation; PTSD; Merck partnership; Minerva Neurosciences; schizophrenia therapy
Eli Lilly Picks Houston for $6.5 Billion API Manufacturing Facility
Eli Lilly; Houston; API manufacturing; $6.5 billion investment; Generation Park; small molecule medicines; pharmaceutical manufacturing; cardiometabolic; oncology; immunology; neuroscience
AbbVie Buys Gilgamesh’s Psychedelic Drug Bretisilocin for $1.2B
AbbVie; Gilgamesh Pharmaceuticals; psychedelic drug; bretisilocin; GM-2505; major depressive disorder; acquisition; mental health; neuroscience; pharmaceutical deal
Reunion Psychedelic Therapy Advances to Pivotal Trials after Postpartum Depression Success
Reunion Neuroscience; RE104; psychedelic therapy; postpartum depression (PPD); Phase II trial; Phase III trial; RECONNECT trial; clinical trial results; Montgomery-Åsberg Depression Rating Scale (MADRS); remission rates
AbbVie Raises 2025 Guidance and Eyes Strategic Deals in Neuroscience, Obesity, and Oncology
AbbVie; 2025 guidance; earnings; neuroscience; obesity; PD-1/VEGF; strategic deals; pharmaceuticals
Deal Roundup: Novartis Options Sironax’s Neuro Platform, Plus Moves from Revolution, Iambic, Sernova, and Eledon
Novartis; Sironax; Brain Delivery Module; neuroscience; blood-brain barrier; biotech; dealmaking; Revolution Medicines; Iambic; Sernova; Eledon
ALTO-203 Misses Depression Endpoint but Shows Positive Biomarker and Cognitive Signals
ALTO-203; Alto Neuroscience; Phase 2 trial; major depressive disorder; EEG biomarkers; theta/beta ratio; attention; wakefulness; William Blair; drug activity; future development
AbbVie Commits $335M Upfront in Landmark siRNA Deal With ADARx
AbbVie; ADARx Pharmaceuticals; siRNA therapeutics; gene silencing; neuroscience; immunology; oncology; biotech partnerships; RNA technology; drug development
Major Clinical Trial Failures of 2024: Setbacks in Neuroscience and Beyond
Clinical trials, drug development, neuroscience, ALS, Alzheimer’s disease, schizophrenia, Duchenne muscular dystrophy, oncology